• Global license provides American Regent, a wholly owned subsidiary of Daiichi Sankyo, with rights to commercialize Synoglide™ in the veterinary market […]
Liege, Belgium – 7 October 2025 (08:30 CET) – Allegro NV, a biomedical company developing transformative nanotechnology-based treatments for degenerative joint disease, today […]
Liege, Belgium – 3 September 2025 (08:30) – Allegro NV, a biomedical company developing transformative nanotechnology-based treatments for degenerative joint disease, has […]
Liege, Belgium – 3 July 2025 – Allegro NV, a biomedical company developing transformative nanotechnology-based treatments for degenerative joint disease, has successfully […]
Allegro was featured in the Noshaq Stories this month with a full feature article in French. Read the full article below or […]
Liege, Belgium – 11 April 2025 (17:00 CET) – Allegro NV, a biomedical company developing transformative nanotechnology-based treatments for degenerative joint disease, […]
Liege, Belgium – 25 March 2025 (08:30 CET) – Allegro NV, a biomedical company developing transformative nanotechnology-based treatments for degenerative joint disease, […]
Liege, Belgium – 4 March 2025 (08:30 CET) – Allegro NV, a biomedical company developing a transformative nanotechnology-based treatment for degenerative joint […]
Liège 17 February 2025 – Allegro, a pioneering biomedical company from Belgium, has won the prestigious Companion Animals Prize for its hydrocelin […]
Allegro is Heading to the Biotech Showcase in San Francisco! We’re excited to announce that Allegro will be attending the Biotech Showcase […]